Fig. 7
αPD1 synergizes RT/TMZ/PL but not RT/TMZ to achieve substantial immune cure in G422TN-mice. A Schematic diagram depicting the PL, RT, TMZ, αPD1, or their combined regimen started on day 7 p.i. αPD1, 6 doses of αPD1 with once oral gavage of 200 µg/mouse except for first dose (400 µg/mouse). B and C The Kaplan-Meier survivals and body weight changes of the G422TN-mice with PL, TR, TMZ, αPD1, or their combined regimen started on day 7 p.i. (n = 8/group). D and E Representative bioluminescent images and the Kaplan-Meier survivals of control (n = 7), RT/TMZ/PL/αPD1 (LTS, n = 4), RT/TMZ/αPD1 (LTS, n = 1) and RT/TMZ/PL (LTS, n = 1) group during rechallenge. (*P < 0.05; ns, not statistically significant)